PharmaDrug Announces Amendment to Shareholder Meeting Matter

About this update from Pharmadrug, Inc.

[{"type":"text","content":"PharmaDrug Announces Amendment to Shareholder Meeting MatterToronto, Ontario--(Newsfile Corp. - September 19, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (\"PharmaDrug\" or the \"Company\"), announced today that, further to its press release dated September 6, 2023, Mr. Daniel Cohen will not be standing for re-election as a director of the Company at the upcoming annual and special meeting of the Company's shareholders to be held on October 13, 2023 at 10:00 a.m. (Toronto time) and he will instead be replaced by Mr. Robert J. Steen, who replaced Mr. Cohen as a director on September 6, 2023. The size of the board will remain at five directors.Information regarding the other director nominees can be found in the Company's Management Information Circular dated August 29, 2023 (the \"Circular\") which is available on SEDAR+ at www.sedarplus.ca and the Company's website. The information required by applicable securities laws to be provided with respect to director nominees in respect of Mr. Steen is set forth below.Mr. Steen is a resident of Ontario, Canada who has had a long career of successful entrepreneurship. He has helped found and develop several businesses in several sectors including real estate acquisition and property management as well as financial tax products and consultancy. Most recently, Robert founded Trafalgar Addiction Treatment Centres in 2012 and helped develop the business until it was sold to a conglomerate in 2022. Since the sale of this business Robert has been a private investor. Robert has an M.B.A. from the Schulich School of Business. Mr. Steen does not serve as a director of any other reporting issuer and does not beneficially own or control any shares of the Company. Finally, in accordance with applicable securities laws we confirm that neither Mr. Steen nor any personal holding company of Mr. Steen:(a) is, as at date hereof, or has been, within the 10 years before the date hereof, a director, chief executive officer or chief financial officer of any company (including the Company) that: (i) was subject to an order that was issued while the proposed director was acting in the capacity as a director, chief executive officer or chief financial officer of the company; or(ii) was subject to an order that was issued after the proposed director ceased to be a director, chief executive officer or chief...

More updates from Pharmadrug, Inc.